Japanese Ministry of Health and Welfare and the US Food and Drug Administration • monitor the number of new applications for the centralised procedure compared to the number of new active substances launched in 2000 and 2001 by the pharmaceutical industry within EU and worldwide • continue to contribute to the internal quality management system (QMS), including to the EMEA QMS manual and support to internal auditing